NEW YORK (GenomeWeb) – Interpace Diagnostics said today that Blue Cross Blue Shield of Florida will begin covering the firm's ThyGenX and ThyraMir molecular thyroid tests.
The ThyGenX oncogene panel and ThyraMir microRNA gene expression classifier are used together to diagnose thyroid nodules with indeterminate cytology. The combination testing includes the rule-in properties of next-generation sequencing of a patient's DNA and RNA, and the rule-out capabilities of a miRNA classifier, according to Interpace.
With the coverage decision, the tests will be available to Blue Cross Blue Shield of Florida's more than 3 million members, the company said.
"We are pleased that the largest payer in the State of Florida, and one of the largest Blue Cross Blue Shield plans in the country, is now covering our molecular thyroid tests," Interpace President and CEO Jack Stover said in a statement. "This continues the strong trend we have seen among Blue Cross Blue Shield plans to make our ThyGenX [and] ThyraMir combination test available to their members."
This year alone, Blue Shield of California; Blue Cross Blue Shield of Arizona; Blue Cross Blue Shield of South Carolina; Wellmark Blue Cross Blue Shield of Iowa; Wellmark Blue Cross Blue Shield of South Dakota; and Horizon Blue Cross Blue Shield of New Jersey all began covering the tests.